Bruno Fantin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1391545/publications.pdf

Version: 2024-02-01

165	6,061	66343	95266
papers	citations	42 h-index	68 g-index

212	212	212	6729
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. Journal of Infection, 2020, 81, e4-e6.	3.3	767
2	Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection Models. Journal of Infectious Diseases, 1989, 159, 281-292.	4.0	357
3	Prediction of the intestinal resistome by a three-dimensional structure-based method. Nature Microbiology, 2019, 4, 112-123.	13.3	129
4	Host Factors and Portal of Entry Outweigh Bacterial Determinants To Predict the Severity of Escherichia coli Bacteremia. Journal of Clinical Microbiology, 2011, 49, 777-783.	3.9	123
5	In vivo antibiotic synergism: contribution of animal models. Antimicrobial Agents and Chemotherapy, 1992, 36, 907-912.	3.2	121
6	A 5-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: a randomized clinical trial. Clinical Microbiology and Infection, 2019, 25, 830-838.	6.0	106
7	Ciprofloxacin Dosage and Emergence of Resistance in Human Commensal Bacteria. Journal of Infectious Diseases, 2009, 200, 390-398.	4.0	105
8	Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 1995, 39, 400-405.	3.2	97
9	The French Gaucherâ€™s disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet Journal of Rare Diseases, 2012, 7, 77.	2.7	97
10	Resolution of Clostridium difficileâ€“Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. Journal of Clinical Oncology, 2013, 31, 2493-2499.	1.6	93
11	Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli. Journal of Antimicrobial Chemotherapy, 1991, 27, 829-836.	3.0	92
12	Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrobial Agents and Chemotherapy, 1991, 35, 1413-1422.	3.2	89
13	Evaluation of the Management of Postoperative Aseptic Meningitis. Clinical Infectious Diseases, 2007, 44, 1555-1559.	5.8	86
14	Medical complications following splenectomy. Journal of Visceral Surgery, 2016, 153, 277-286.	0.8	86
15	Resistance to Quinupristin-Dalfopristin Due to Mutation of L22 Ribosomal Protein in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2002, 46, 2200-2207.	3.2	84
16	Imaging does not predict the clinical outcome of bacterial vertebral osteomyelitis. Rheumatology, 2006, 46, 292-295.	1.9	84
17	Comparative study of postoperative and spontaneous pyogenic spondylodiscitis. Seminars in Arthritis and Rheumatism, 2005, 34, 766-771.	3.4	80
18	Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrobial Agents and Chemotherapy, 1990, 34, 2387-2391.	3.2	74

#	Article	IF	Citations
19	Mutator phenotype confers advantage inEscherichia colichronic urinary tract infection pathogenesis. FEMS Immunology and Medical Microbiology, 2005, 44, 317-321.	2.7	71
20	Impact of Low-Level Resistance to Fluoroquinolones Due to qnrA1 and qnrS1 Genes or a gyrA Mutation on Ciprofloxacin Bactericidal Activity in a Murine Model of Escherichia coli Urinary Tract Infection. Antimicrobial Agents and Chemotherapy, 2009, 53, 4292-4297.	3.2	71
21	Selection of Glycopeptide-Resistant Mutants of VanB-Type Enterococcus faecaiis BM4281 In Vitro and in Experimental Endocarditis. Journal of Infectious Diseases, 1997, 175, 598-605.	4.0	67
22	Association between Nasal Carriage of Staphylococcus Aureus and Infection in Liver Transplant Recipients. Clinical Infectious Diseases, 2000, 31, 1295-1299.	5.8	67
23	Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. Antimicrobial Agents and Chemotherapy, 2003, 47, 216-222.	3.2	67
24	Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 1994, 33, 563-569.	3.0	66
25	Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clinical Microbiology and Infection, 2011, 17, 557-565.	6.0	65
26	Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and Teicoplanin. Antimicrobial Agents and Chemotherapy, 2004, 48, 1061-1064.	3.2	61
27	Activity and Diffusion of LY333328 in Experimental Endocarditis Due to Vancomycin-Resistant Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 1999, 43, 115-120.	3.2	60
28	Activity of LY333328 Combined with Gentamicin In Vitro and in Rabbit Experimental Endocarditis Due to Vancomycin-Susceptible or -Resistant Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 2000, 44, 3017-3021.	3.2	57
29	Behcetâ€™s disease in budd-chiari syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 104.	2.7	57
30	Lyme borreliosis and other tick-borne diseases. Guidelines from the French Scientific Societies (I): prevention, epidemiology, diagnosis. MÃ©decine Et Maladies Infectieuses, 2019, 49, 318-334.	5.0	55
31	Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scandinavian Journal of Infectious Diseases, Supplement, 1990, 74, 179-84.	0.3	55
32	Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like beta-lactamase. Antimicrobial Agents and Chemotherapy, 1990, 34, 581-586.	3.2	53
33	Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.. Antimicrobial Agents and Chemotherapy, 1991, 35, 1570-1575.	3.2	53
34	Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis. Antimicrobial Agents and Chemotherapy, 1997, 41, 931-935.	3.2	53
35	Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19. Journal of Infection, 2020, 81, e96-e98.	3.3	53
36	Accuracy and Potential Usefulness of Triplex Real-Time PCR for Improving Antibiotic Treatment of Patients with Blood Cultures Showing Clustered Gram-Positive Cocci on Direct Smears. Journal of Clinical Microbiology, 2008, 46, 2045-2051.	3.9	52

#	Article	IF	Citations
37	Acute cholangitis: Diagnosis and management. Journal of Visceral Surgery, 2019, 156, 515-525.	0.8	52
38	In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrobial Agents and Chemotherapy, 1994, 38, 432-437.	3.2	51
39	Characteristics of and risk factors for severe neurological deficit in patients with pyogenic vertebral osteomyelitis. Medicine (United States), 2017, 96, e6387.	1.0	50
40	HypervirulentKlebsiella pneumoniaein Cryptogenic Liver Abscesses, Paris, France. Emerging Infectious Diseases, 2018, 24, 221-229.	4.3	47
41	Spinal Tuberculosis: A Longitudinal Study with Clinical, Laboratory, and Imaging Outcomes. Seminars in Arthritis and Rheumatism, 2006, 36, 124-129.	3.4	45
42	Three-Month Antibiotic Therapy for Early-Onset Postoperative Spinal Implant Infections. Clinical Infectious Diseases, 2012, 55, 1481-1487.	5.8	45
43	Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone. Journal of Antimicrobial Chemotherapy, 2014, 69, 3393-3400.	3.0	45
44	Risk factors forEnterobacteriaceaebacteremia after liver transplantation. Transplant International, 2008, 21, 755-763.	1.6	43
45	Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis. Antimicrobial Agents and Chemotherapy, 1989, 33, 767-770.	3.2	42
46	Pharmacokinetics and Pharmacodynamics of Temocillin. Clinical Pharmacokinetics, 2018, 57, 287-296.	3.5	42
47	Acquired Gentamicin Resistance by Permeability Impairment in Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 2006, 50, 3615-3621.	3.2	41
48	Cefoxitin as an Alternative to Carbapenems in a Murine Model of Urinary Tract Infection Due to Escherichia coli Harboring CTX-M-15-Type Extended-Spectrum Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2012, 56, 1376-1381.	3.2	41
49	Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiology, 2015, 10, 1241-1255.	2.0	41
50	Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies (II). Biological diagnosis, treatment, persistent symptoms after documented or suspected Lyme borreliosis. MÃ©decine Et Maladies Infectieuses, 2019, 49, 335-346.	5.0	41
51	Mortality in Escherichia coli bloodstream infections: antibiotic resistance still does not make it. Journal of Antimicrobial Chemotherapy, 2020, 75, 2334-2343.	3.0	41
52	Technetium 99mâ€“Labeled Annexin V Scintigraphy of Platelet Activation in Vegetations of Experimental Endocarditis. Circulation, 2008, 117, 781-789.	1.6	39
53	Lymphocyte Subset Counts During the Course of Community-Acquired Pneumonia: Evolution According to Age, Human Immunodeficiency Virus Status, and Etiologic Microorganisms. Clinical Infectious Diseases, 1996, 22, 1096-1098.	5.8	38
54	Clinical Evaluation of the Management of Community-Acquired Pneumonia by General Practitioners in France. Chest, 2001, 120, 185-192.	0.8	36

#	Article	IF	Citations
55	Ferritinemia during type 1 Gaucher disease: Mechanisms and progression under treatment. Blood Cells, Molecules, and Diseases, 2012, 49, 53-57.	1.4	35
56	Ciprofloxacin Treatment Failure in a Murine Model of Pyelonephritis Due to an AAC(6â€²)-Ib-cr-Producing Escherichia coli Strain Susceptible to Ciprofloxacin In Vitro. Antimicrobial Agents and Chemotherapy, 2013, 57, 5830-5835.	3.2	34
57	Clinical predictive values of extended-spectrum beta-lactamase carriage in patients admitted to medical wards. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 319-325.	2.9	33
58	Single daily dosing of antibiotics: importance of in vitro killing rate, serum half-life, and protein binding. Antimicrobial Agents and Chemotherapy, 1991, 35, 2085-2090.	3.2	32
59	Activities of the Combination of Quinupristin-Dalfopristin with Rifampin In Vitro and in Experimental Endocarditis Due to Staphylococcus aureus Strains with Various Phenotypes of Resistance to Macrolide-Lincosamide-Streptogramin Antibiotics. Antimicrobial Agents and Chemotherapy, 2001, 45, 1244-1248.	3.2	31
60	Diversity of Individual Dynamic Patterns of Emergence of Resistance to Quinolones in Escherichia coli From the Fecal Flora of Healthy Volunteers Exposed to Ciprofloxacin. Journal of Infectious Diseases, 2012, 206, 1399-1406.	4.0	31
61	Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 1993, 37, 2466-2469.	3.2	29
62	Antibiotic use: knowledge and perceptions in two university hospitals. Journal of Antimicrobial Chemotherapy, 2011, 66, 936-940.	3.0	29
63	Activity of temocillin in a murine model of urinary tract infection due to Escherichia coli producing or not producing the ESBL CTX-M-15. Journal of Antimicrobial Chemotherapy, 2015, 70, 1466-1472.	3.0	29
64	Efficacies of Quinupristin-Dalfopristin Combined with Vancomycin In Vitro and in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus in Relation to Cross-Resistance to Macrolides, Lincosamides, and Streptogramin B- Type Antibiotics. Antimicrobial Agents and Chemotherapy, 2002, 46, 3061-3064.	3.2	28
65	Autochthonous Case of Eosinophilic Meningitis Caused by Angiostrongylus cantonensis, France, 2016. Emerging Infectious Diseases, 2017, 23, 1045-1046.	4.3	28
66	A nomogram to predict the risk of unfavourable outcome in COVID-19: a retrospective cohort of 279 hospitalized patients in Paris area. Annals of Medicine, 2020, 52, 367-375.	3.8	28
67	Two-Step Acquisition of Resistance to the Teicoplanin-Gentamicin Combination by VanB-Type Enterococcus faecalis In Vitro and in Experimental Endocarditis. Antimicrobial Agents and Chemotherapy, 1999, 43, 476-482.	3.2	27
68	Independent Behavior of Commensal Flora for Carriage of Fluoroquinolone-Resistant Bacteria in Patients at Admission. Antimicrobial Agents and Chemotherapy, 2010, 54, 5193-5200.	3.2	27
69	Costs associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France. BMJ Open, 2016, 6, e009029.	1.9	26
70	Plasmidic qnrA3 Enhances Escherichia coli Fitness in Absence of Antibiotic Exposure. PLoS ONE, 2011, 6, e24552.	2.5	26
71	Impact of dosage schedule on the efficacy of gentamicin, tobramycin, or amikacin in an experimental model of Serratia marcescens endocarditis: in vitro-in vivo correlation. Antimicrobial Agents and Chemotherapy, 1991, 35, 111-116.	3.2	25
72	Risk Factors forClostridium difficileInfection in a Hepatology Ward. Infection Control and Hospital Epidemiology, 2007, 28, 202-204.	1.8	23

#	Article	IF	Citations
73	Ceftriaxone promotes the emergence of AmpC-overproducing Enterobacteriaceae in gut microbiota from hospitalized patients. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 417-421.	2.9	23
74	Activity of temocillin in a lethal murine model of infection of intra-abdominal origin due to KPC-producingEscherichia coli. Journal of Antimicrobial Chemotherapy, 2016, 71, 1899-1904.	3.0	22
75	Influence of Resistance to Streptogramin A Type Antibiotics on the Activity of Quinupristin-Dalfopristin In Vitro and in Experimental Endocarditis Due to Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2000, 44, 1168-1173.	3.2	21
76	Invasive actinomycosis: surrogate marker of a poor prognosis in immunocompromised patients. International Journal of Infectious Diseases, 2014, 29, 74-79.	3.3	21
77	Metagenomic Characterization of Gut Microbiota of Carriers of Extended-Spectrum Beta-Lactamase or Carbapenemase-Producing Enterobacteriaceae Following Treatment with Oral Antibiotics and Fecal Microbiota Transplantation: Results from a Multicenter Randomized Trial. Microorganisms, 2020, 8, 941.	3.6	21
78	Tuberculous cerebral vasculitis: Retrospective study of 10 cases. European Journal of Internal Medicine, 2011, 22, e99-e104.	2.2	20
79	Activity of Gemifloxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2005, 49, 1046-1054.	3.2	19
80	Do Case Vignettes Accurately Reflect Antibiotic Prescription?. Infection Control and Hospital Epidemiology, 2011, 32, 1003-1009.	1.8	19
81	Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease. Blood Cells, Molecules, and Diseases, 2011, 46, 34-38.	1.4	19
82	Ecological impact of ciprofloxacin on commensal enterococci in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2017, 72, 1574-1580.	3.0	19
83	Influence of Reduced Susceptibility to Glycopeptides on Activities of Vancomycin and Teicoplanin against Staphylococcus aureus in Experimental Endocarditis. Antimicrobial Agents and Chemotherapy, 2003, 47, 2018-2021.	3.2	18
84	Amoxicillin Is Effective against Penicillin-Resistant Streptococcus pneumoniae Strains in a Mouse Pneumonia Model Simulating Human Pharmacokinetics. Antimicrobial Agents and Chemotherapy, 2007, 51, 208-214.	3.2	18
85	Escherichia colibacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome. Epidemiology and Infection, 2014, 142, 2672-2683.	2.1	18
86	Comparative dynamics of the emergence of fluoroquinolone resistance in staphylococci from the nasal microbiota of patients treated with fluoroquinolones according to their environment. International Journal of Antimicrobial Agents, 2015, 46, 653-659.	2.5	18
87	Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection. International Journal of Medical Microbiology, 2017, 307, 452-459.	3.6	18
88	Activity of fosfomycin alone or combined with temocillin in vitro and in a murine model of peritonitis due to KPC-3- or OXA-48-producing Escherichia coli. Journal of Antimicrobial Chemotherapy, 2018, 73, 3074-3080.	3.0	18
89	Bactericidal Activity of Gentamicin against Enterococcus faecalis In Vitro and In Vivo. Antimicrobial Agents and Chemotherapy, 2000, 44, 2077-2080.	3.2	17
90	Management of acute community-acquired bacterial meningitis (excluding newborns). Short text. MÃ©decine Et Maladies Infectieuses, 2019, 49, 367-398.	5.0	17

#	Article	IF	Citations
91	Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies. MÃ©decine Et Maladies Infectieuses, 2019, 49, 296-317.	5.0	17
92	Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 1996, 40, 1219-1224.	3.2	16
93	Acute pulmonary embolism. European Journal of Gastroenterology and Hepatology, 2004, 16, 1241-1244.	1.6	16
94	Antimicrobial Treatment of Febrile Neutropenia: Pharmacokineticâ€“Pharmacodynamic Considerations. Clinical Pharmacokinetics, 2013, 52, 869-883.	3.5	16
95	Quinolone-resistant Escherichia coli from the faecal microbiota of healthy volunteers after ciprofloxacin exposure are highly adapted to a commensal lifestyle. Journal of Antimicrobial Chemotherapy, 2014, 69, 761-768.	3.0	16
96	Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum Î²-lactamase. International Journal of Antimicrobial Agents, 2014, 43, 366-369.	2.5	16
97	Immunoglobulin Abnormalities in Gaucher Disease: an Analysis of 278 Patients Included in the French Gaucher Disease Registry. International Journal of Molecular Sciences, 2020, 21, 1247.	4.1	16
98	Efficacy of Cethromycin, a New Ketolide, against Streptococcus pneumoniae Susceptible or Resistant to Erythromycin in a Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2006, 50, 3033-3038.	3.2	15
99	Bactericidal Activity of the Combination of Levofloxacin with Rifampin in Experimental Prosthetic Knee Infection in Rabbits Due to Methicillin-Susceptible Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 2009, 53, 2145-2148.	3.2	15
100	The In Vitro Contribution of Autolysins to Bacterial Killing Elicited by Amoxicillin Increases with Inoculum Size in Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 2011, 55, 910-912.	3.2	15
101	Influence of antimicrobial therapy on kinetics of tumor necrosis factor levels in experimental endocarditis caused by Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 1994, 38, 1017-1022.	3.2	14
102	Relationship between the Level of Acquired Resistance to Gentamicin and Synergism with Amoxicillin in Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4144-4148.	3.2	14
103	Critical Importance of In Vivo Amoxicillin and Cefotaxime Concentrations for Synergy in Treatment of Experimental Enterococcus faecalis Endocarditis. Antimicrobial Agents and Chemotherapy, 1998, 42, 468-470.	3.2	14
104	Expression of Glycopeptideâ€Resistance Gene in Response to Vancomycin and Teicoplanin in the Cardiac Vegetations of Rabbits Infected with VanBâ€TypeEnterococcus faecalis. Journal of Infectious Diseases, 2004, 189, 90-97.	4.0	13
105	Faecal microbiota transplantation with frozen capsules for relapsing Clostridium difficile infections: the first experience from 15 consecutive patients in France. Journal of Hospital Infection, 2018, 100, 148-151.	2.9	13
106	Cervical involvement in SAPHO syndrome: imaging findings with a 10-year follow-up. Skeletal Radiology, 2003, 32, 103-106.	2.0	12
107	Activities of Garenoxacin against Quinolone-Resistant Streptococcus pneumoniae Strains In Vitro and in a Mouse Pneumonia Model. Antimicrobial Agents and Chemotherapy, 2004, 48, 765-773.	3.2	12
108	Reduced Antibiotic Pressure for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Back to the Future. Clinical Infectious Diseases, 2010, 51, 150-152.	5.8	12

#	Article	IF	Citations
109	Broad-Range 16S rRNA PCR with Cerebrospinal Fluid May Be Unreliable for Management of Postoperative Aseptic Meningitis. Journal of Clinical Microbiology, 2010, 48, 3331-3333.	3.9	11
110	Flow Cytometry as a Tool To Determine the Effects of Cell Wall-Active Antibiotics on Vancomycin-Susceptible and -Resistant Enterococcus faecalis Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 395-398.	3.2	11
111	An outbreak of Pneumocytis jirovecii pneumonia among liver transplant recipients. Transplant Infectious Disease, 2018, 20, e12956.	1.7	11
112	Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases, 2021, 107, 86-91.	3.3	11
113	Contribution of animal models of infection for the evaluation of the activity of antimicrobial agents. International Journal of Antimicrobial Agents, 1997, 9, 73-82.	2.5	10
114	Contribution of the Autolysin AtlA to the Bactericidal Activity of Amoxicillin against Enterococcus faecalis JH2-2. Antimicrobial Agents and Chemotherapy, 2009, 53, 1667-1669.	3.2	10
115	Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-Î²-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 424-430.	3.2	10
116	Novel Chromosomal Mutations Responsible for Fosfomycin Resistance in Escherichia coli. Frontiers in Microbiology, 2020, 11, 575031.	3.5	10
117	Acute respiratory failure due to diaphragmatic weakness revealing a polymyositis. European Journal of Internal Medicine, 2002, 13, 203-205.	2.2	9
118	Recurrent valvular replacement due to exacerbation of Behcetâ€™s disease by Streptococcus agalactiae infection. European Journal of Internal Medicine, 2003, 14, 120-122.	2.2	9
119	Schnitzlerâ€™s syndrome: 3-year radiological follow-up. Skeletal Radiology, 2006, 36, 153-156.	2.0	9
120	Surgery is safe and effective when indicated in the acute phase of hematogenous pyogenic vertebral osteomyelitis. Infectious Diseases, 2019, 51, 268-276.	2.8	9
121	Prospective Cohort Study of the Relative Abundance of Extended-Spectrum-Beta-Lactamase-Producing Escherichia coli in the Gut of Patients Admitted to Hospitals. Antimicrobial Agents and Chemotherapy, 2016, 60, 6941-6944.	3.2	8
122	RÃ©sistance aux fluoroquinolones en 2010Â: quel impact pour la prescription en rÃ©animationÂ?. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2010, 19, 347-353.	0.1	7
123	Management of adult infectious encephalitis in metropolitan France. MÃ©decine Et Maladies Infectieuses, 2017, 47, 206-220.	5.0	7
124	The inoculum effect of Escherichia coli expressing mcr-1 or not on colistin activity in a murine model of peritonitis. Clinical Microbiology and Infection, 2019, 25, 1563.e5-1563.e8.	6.0	7
125	Unexpected Activity of Oral Fosfomycin against Resistant Strains of Escherichia coli in Murine Pyelonephritis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	7
126	Analysis of Paradoxical Efficacy of Carbapenems against Carbapenemase-Producing Escherichia coli in a Murine Model of Lethal Peritonitis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7

#	Article	IF	Citations
127	Critical influence of timing of administration of granulocyte colony-stimulating factor on antibacterial effect in experimental endocarditis due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 1995, 39, 2702-2707.	3.2	6
128	Consequences of VanE-Type Resistance on Efficacy of Glycopeptides In Vitro and in Experimental Endocarditis Due to Enterococcus faecalis. Antimicrobial Agents and Chemotherapy, 2001, 45, 2826-2830.	3.2	6
129	Hypoparathyroidism preceding Riedelâ€™s thyroiditis. European Journal of Internal Medicine, 2003, 14, 202-204.	2.2	6
130	Presentation and impact of catheter-associated thrombosis in patients with infected long-term central venous catheters: a prospective bicentric observational study. Annals of Medicine, 2016, 48, 182-189.	3.8	6
131	Cytomegalovirus-associated protein-losing enteropathy in a healthy man. MÃ©decine Et Maladies Infectieuses, 2017, 47, 562-565.	5.0	6
132	Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates. Journal of Antimicrobial Chemotherapy, 2019, 74, 1323-1326.	3.0	6
133	Pyogenic liver abscess in liver transplant recipient: A warning signal for the risk of recurrence and retransplantation. Transplant Infectious Disease, 2020, 22, e13360.	1.7	6
134	Travel-related health events and their risk factors in HIV-infected sub-Saharan migrants living in France and visiting their native country: The ANRS VIHVO cohort study. Travel Medicine and Infectious Disease, 2019, 29, 40-47.	3.0	5
135	More complications in cervical than in non-cervical spine tuberculosis. Infectious Diseases, 2020, 52, 170-176.	2.8	5
136	Dimercaptosuccinic acid in combination with carbapenems against isogenic strains of Escherichia coli producing or not producing a metallo-Î²-lactamase in vitro and in murine peritonitis. Journal of Antimicrobial Chemotherapy, 2020, 75, 3593-3600.	3.0	5
137	Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model. Clinical Microbiology and Infection, 2020, 26, 1416.e5-1416.e9.	6.0	5
138	Pharmacokinetic and pharmacodynamic aspects of therapy of experimental endocarditis. Infectious Disease Clinics of North America, 1993, 7, 37-51.	5.1	5
139	Influence of VanD Type Resistance on Activities of Glycopeptides In Vitro and in Experimental Endocarditis Due to Enterococcus faecium. Antimicrobial Agents and Chemotherapy, 2003, 47, 3515-3518.	3.2	4
140	qnrA6genetic environment and quinolone resistance conferred onProteus mirabilis. Journal of Antimicrobial Chemotherapy, 2016, 71, 903-908.	3.0	4
141	Physicians fail to consider Pseudomonas aeruginosa as a potential pathogen in medicine patients with bacteremia. Journal of Infection, 2011, 63, 99-101.	3.3	3
142	Characteristics of vertebral osteomyelitis after liver transplantation. Clinical Microbiology and Infection, 2015, 21, 573-577.	6.0	3
143	Effect of a Red Blood Cell Transfusion on Biological Markers Used to Determine the Cause of Anemia: A Prospective Study. American Journal of Medicine, 2018, 131, 319-322.	1.5	3
144	Increased mortality in patients aged 75 years or over with pyogenic vertebral osteomyelitis. Infectious Diseases, 2018, 50, 783-787.	2.8	3

#	Article	IF	Citations
145	Activity of the combination of colistin and fosfomycin against NDM-1-producing Escherichia coli with variable levels of susceptibility to colistin and fosfomycin in a murine model of peritonitis. Journal of Antimicrobial Chemotherapy, 2021, 77, 155-163.	3.0	3
146	Spontaneous and postsurgical/traumatic Klebsiella pneumoniae meningitis: two distinct clinico-microbiological entities. International Journal of Infectious Diseases, 2022, 114, 185-191.	3.3	3
147	Multifocal osteonecrosis after chemotherapy in a patient with breast cancer. Journal of Rheumatology, 1998, 25, 2479-80.	2.0	3
148	Bone involvement in generalized crystal-storing histiocytosis. Journal of Rheumatology, 2006, 33, 2354-8.	2.0	3
149	Salmonella Colindale osteomyelitis in an immunocompetent female patient. MÃ©decine Et Maladies Infectieuses, 2012, 42, 36-37.	5.0	2
150	Flagellate erythema in systemic sclerosis: A case report. JAAD Case Reports, 2018, 4, 239-241.	0.8	2
151	Temocillin as an alternative treatment for acute bacterial cholangitis: a retrospective microbiology susceptibility-based study of 140 episodes. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1773-1777.	2.9	2
152	ActualitÃ©s sur la prise en charge des abcÃ¨s cÃ©rÃ©braux de lâ€™adulte. Antibiotiques, 2008, 10, 106-114.	0.1	1
153	Differences in daptomycin and vancomycin ex vivo behaviour can lead to false interpretation of negative blood cultures. Clinical Microbiology and Infection, 2011, 17, 1264-1267.	6.0	1
154	AngiocholitesÂ: diagnostic et prise en charge. Journal De Chirurgie ViscÃ©rale, 2019, 156, 552-563.	0.0	1
155	Early primary toxoplasmosis transmitted by liver graft: A case report. Infectious Diseases Now, 2021, 51, 315-316.	1.6	1
156	Evolution of fluoroquinolone-resistant Escherichia coli in the gut after ciprofloxacin treatment. International Journal of Medical Microbiology, 2022, 312, 151548.	3.6	1
157	Infections sur materiel d'osteosynthese. MÃ©decine Et Maladies Infectieuses, 1987, 17, 357.	5.0	0
158	Pression de sÃ©lection des antibiotiques: donnÃ©es expÃ©rimentales. Reanimation Urgences, 1999, 8, 1s-4s.	0.1	0
159	De la colonie microbienne Ã lâ€™infection chez lâ€™homme : le cas de Pseudomonas aeruginosa, importance thÃ©rapeutique. Antibiotiques, 2004, 6, 241-248.	0.1	0
160	ModÃ¨les expÃ©rimentauxÂ: quelsÂmodÃ¨les peuvent encore apporter desÂinformations dansÂleÂtraitement desÂinfections bactÃ©riennesÂ?. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2006, 15, 214-220.	0.1	0
161	Arthrite septique destructrice Ã Ureaplasma urealyticum aprÃ¨s un traitement par rituximab chez un patient atteint de lupus Ã©rythÃ©mateux systÃ©mique. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 296-297.	0.0	0
162	Monoclonal gammopathies and hypergammaglobulemia in Gaucher disease: An analysis from the French Gaucher disease registry. Molecular Genetics and Metabolism, 2019, 126, S107.	1.1	0

#	Article	IF	Citations
163	Different kinetics of infectious processes in vertebral osteomyelitis of pyogenic or tuberculous origin explain different timing of surgery. Infectious Diseases, 2020, 52, 563-570.	2.8	0
164	Vancomycine (Vm) et teicoplanine (Te) dans l'endocardite expÃ©rimentale du lapin due Ã de phÃ©notype vanB : activitÃ© et sÃ©lection de variants rÃ©sistants. MÃ©decine Et Maladies Infectieuses, 1996, 26, 882-883.	5.0	0
165	Polyvalent 23 epitope polysaccharide pneumonia vaccine induced effective protection through strain-adapted effector mechanisms as demonstrated by the different cytokine responses in mice challenged with two different strains of Streptococcus pneumoniae. European Cytokine Network, 2007, 18, 23-30.	2.0	0